Markets:

Overview

News

Currencies

International

Treasuries

Organon & Co. Common Stock (NY:OGN)

13.79 UNCHANGED

Delayed Quote Updated: 1:52 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

This House of Representative Just Sold Up To $30K In Organon Stock ↗

August 13, 2026

A report on August 12, 2026 shows that Representative Kevin Hern from Oklahoma sale stock in Organon (NYSE:OGN), valued between $2,002 and $30,000. According to the August filing, the transaction...

Via Benzinga

Organon & Co. Shareholders Clear Sun Pharma Merger Deal ↗

July 23, 2026

Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to...

Via MarketBeat

Topics Stocks

Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates

April 30, 2026

Pharmaceutical company Organon (NYSE:OGN) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 3.5% year on year to $1.46 billion. Its ...

Via StockStory

Topics Artificial Intelligence

Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal ↗

April 27, 2026

Today, April 27, 2026, a jumbo all-cash buyout and merger-arb dynamics put Organon in focus.

Via The Motley Fool

Topics Stocks

Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook ↗

February 12, 2026

Via Chartmill

Topics Earnings

Monday's session: most active stocks ↗

April 27, 2026

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

April 24, 2026

Via Chartmill

What's going on in today's pre-market session ↗

April 24, 2026

Via Chartmill

3 Reasons to Avoid OGN and 1 Stock to Buy Instead

April 13, 2026

Over the last six months, Organon’s shares have sunk to $9.03, producing a disappointing 5.9% loss - a stark contrast to the S&P 500’s 2.5% gain. This may ha...

Via StockStory

Topics Stocks

Traders are paying attention to the gapping stocks in Friday's session. ↗

April 10, 2026

Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Topics Artificial Intelligence

Discover the top movers in Friday's pre-market session. ↗

April 10, 2026

Wondering what's happening in Friday's pre-market session? Find an overview in this article.

Via Chartmill

Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know

April 06, 2026

What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci...

Via StockStory

Topics Government Stocks

3 Cash-Producing Stocks We’re Skeptical Of

March 23, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...

Via StockStory

Topics Fraud

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗

March 20, 2026

Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.

Via The Motley Fool

3 Value Stocks We Approach with Caution

March 20, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Via StockStory

1 Stock Under $10 to Own for Decades and 2 That Underwhelm

March 19, 2026

Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re barga...

Via StockStory

3 of Wall Street’s Favorite Stocks We Approach with Caution

March 13, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

3 Small-Cap Stocks We Approach with Caution

March 04, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy

February 26, 2026

As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the...

Via Finterra

Topics Economy

5 Revealing Analyst Questions From Organon’s Q4 Earnings Call

February 19, 2026

Organon's fourth quarter was met with a negative market reaction as operational challenges and shifting demand patterns weighed on results. Management pointed to continued pricing pressure, loss of...

Via StockStory

Topics Earnings

Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Via StockStory

Topics Economy

OGN Q4 Deep Dive: Margin Compression and U.S. Headwinds Shape 2026 Outlook

February 13, 2026

Pharmaceutical company Organon (NYSE:OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5.3% year on year to $1.51 billion. The company’s full-year revenue guidance of $6.2...

Via StockStory

Organon (OGN) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Organon (OGN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations

February 12, 2026

Via StockStory

Organon Earnings: What To Look For From OGN

February 10, 2026

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence World Trade

2 Healthcare Stocks with Promising Prospects and 1 We Brush Off

February 04, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but...

Via StockStory

Topics Stocks

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Nasdaq, S&P 500 Futures Rise As Trump Diffuses Tariff Risk: Why INTC, MSFT, NFLX, RKLB, OGN Are On Traders' Radar Today ↗

January 22, 2026

Retail sentiment on Stocktwits for SPY and QQQ remains ‘bearish,’ signaling caution.

Via Stocktwits

Topics ETFs Earnings Economy

Why Are Organon (OGN) Shares Soaring Today

January 20, 2026

Shares of pharmaceutical company Organon (NYSE:OGN) jumped 8.9% in the afternoon session after reports surfaced that Sun Pharmaceutical Industries submitted a non-binding proposal to acquire the...

Via StockStory

Topics Artificial Intelligence Initial Public Offering Supply Chain

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.